AbCellera Biologics Inc.
ABCL
$3.65
$0.082.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 788.18% | 37.62% | 133.29% | -57.45% | -44.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 788.18% | 37.62% | 133.29% | -57.45% | -44.98% |
| Cost of Revenue | 8.72% | 34.32% | -4.19% | 8.17% | -5.24% |
| Gross Profit | 87.23% | -33.69% | 34.15% | -30.44% | -4.01% |
| SG&A Expenses | -10.15% | 12.01% | -5.75% | -7.96% | 0.47% |
| Depreciation & Amortization | 131.51% | -85.79% | -85.02% | 10.05% | -357.90% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.32% | -14.91% | -33.85% | 3.16% | -39.12% |
| Operating Income | 29.87% | 18.56% | 46.94% | -14.15% | 38.30% |
| Income Before Tax | 58.36% | -9.80% | 24.58% | -23.95% | 3.65% |
| Income Tax Expenses | 16.36% | -1.08% | 85.64% | -244.55% | -769.08% |
| Earnings from Continuing Operations | 73.85% | -11.76% | 5.97% | -12.34% | 27.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 73.85% | -11.76% | 5.97% | -12.34% | 27.44% |
| EBIT | 29.87% | 18.56% | 46.94% | -14.15% | 38.30% |
| EBITDA | 13.76% | -25.18% | 22.51% | -14.54% | 55.50% |
| EPS Basic | 74.27% | -10.27% | 7.33% | -10.45% | 28.69% |
| Normalized Basic EPS | 34.10% | 14.25% | 25.68% | -21.80% | 46.62% |
| EPS Diluted | 73.75% | -10.27% | 7.69% | -9.43% | 31.80% |
| Normalized Diluted EPS | 34.10% | 14.25% | 25.68% | -21.80% | 46.62% |
| Average Basic Shares Outstanding | 1.43% | 1.36% | 1.46% | 1.70% | 1.76% |
| Average Diluted Shares Outstanding | 1.43% | 1.36% | 1.46% | 1.70% | 1.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |